Mirxes Holding Company Limited (Stock Code: 02629, Stock Name: MIRXES-B) has won the bid for the 2026 Lianxi District Gastric Cancer Screening and Early Intervention Project in Lianxi District, Jiujiang. According to the announcement, this marks the company’s first public health early cancer screening program and first government procurement project in China, representing an official entry of its miRNA liquid biopsy technology into the public healthcare system.

The project has a budget of RMB8.10 million, with the maximum bid price set at RMB7.70 million. It aims to provide early gastric cancer screening services to about 30,000 residents, covering approximately 8% of Lianxi District’s population of 418,000—making it the largest public health gastric cancer early screening initiative in that region. The project is expected to improve local early detection rates of gastric cancer and strengthen cancer prevention and control measures.

As stated in the announcement, GASTROClear™ is the first in vitro diagnostics product for gastric cancer screening in China, holding a Class III Medical Device Registration Certificate from the National Medical Products Administration. The successful bid is seen as an important endorsement of the company’s technology and products by the public health sector. Additionally, it is expected to generate experience in national government procurement processes and support future expansions of similar public health programs.

Under the principle of “screening — diagnosis — intervention — follow-up,” this initiative is expected to establish a more comprehensive framework for gastric cancer prevention and treatment in Lianxi District, potentially helping reduce the incidence and mortality of gastric cancer. The announcement also notes that there is no assurance of eventual large-scale commercialization of GASTROClear™ in China.